Jump to main content
Jump to site search

Issue 2, 2021
Previous Article Next Article

In vitro and in vivo models for anti-amyloidosis nanomedicines

Author affiliations

Abstract

Amyloid diseases are global epidemics characterized by the accumulative deposits of cross-beta amyloid fibrils and plaques. Despite decades of intensive research, few solutions are available for the diagnosis, treatment, and prevention of these debilitating diseases. Since the early work on the interaction of human β2-microglobulin and nanoparticles by Linse et al. in 2007, the field of amyloidosis inhibition has gradually evolved into a new frontier in nanomedicine offering numerous interdisciplinary research opportunities, especially for materials, chemistry and biophysics. In this review we summarise, for the first time, the in vitro and in vivo models employed thus far in the field of anti-amyloidosis nanomedicines. Based on this systematic summary, we bring forth the notion that, due to the complex and often overlapping physiopathologies of amyloid diseases, there is a crucial need for the appropriate use of in vitro and in vivo models for validating novel anti-amyloidosis nanomedicines, and there is a crucial need for the development of new animal models that reflect the behavioural, symptomatic and cross-talk hallmarks of amyloid diseases such as Alzheimer's (AD), Parkinson's (PD) diseases and type 2 diabetes (T2DM).

Graphical abstract: In vitro and in vivo models for anti-amyloidosis nanomedicines

Back to tab navigation

Article information


Submitted
17 Sep 2020
Accepted
05 Jan 2021
First published
05 Jan 2021

Nanoscale Horiz., 2021,6, 95-119
Article type
Review Article

In vitro and in vivo models for anti-amyloidosis nanomedicines

A. Kakinen, I. Javed, T. P. Davis and P. C. Ke, Nanoscale Horiz., 2021, 6, 95
DOI: 10.1039/D0NH00548G

Social activity

Search articles by author

Spotlight

Advertisements